Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Open access
Aronne, Louis J., Horn, Deborah Bade, le Roux, Carel W., Ho, Wayne, Falcon, Beverly L., Gomez Valderas, Elisa, Das, Sagar, Lee, Clare J., Glass, Leonard C., Senyucel, Cagri, Dunn, Julia P. · 2025 · New England Journal of Medicine

Abstract

BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2416394

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

15 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 40 references

Cited by

See all 634

Metadata

Authors
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
Affiliations
  • Weill Cornell Medicine (US)
  • University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
  • Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
  • University of California, Los Angeles (US)
  • Eli Lilly, Indianapolis
  • Eli Lilly (United States) (US)
Venue
New England Journal of Medicine
Published
2025-07-03
Volume
393
Issue
1
Pages
26-36
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4410277932
Cited by
634
References
40
Citations by year
2026: 448 · 2025: 186
FWCI
355.83
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
Funders
Eli Lilly and Company (NA)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://app.cochat.ai/papers/10.1056/nejmoa2416394
The paper
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2416394

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.